Burning Rock
Burning Rock, Dizal Get Chinese Approval for Lung Cancer CDx
The test, approved by Chinese regulators in early 2022, is designed for the detection of multiple mutation statuses for nine genes.
In Brief This Week: Burning Rock; AmoyDx; Mindera Health; More
News items for the week of Aug. 19, 2024
Burning Rock, Bayer to Develop NGS-Based Companion Diagnostics in China
The companies will jointly develop next-generation sequencing-based companion diagnostic tests for Bayer's precision cancer therapies.
In Brief This Week: Centogene, Burning Rock, Sophia Genetics, Prenetics, More
News items for the week of April 4, 2024
Burning Rock Receives Nasdaq Delisting Warning
The company said it will closely monitor its shares' closing bid price and work to regain compliance with the required $1.00 minimum.
Nov 30, 2023
Burning Rock Biotech Q3 Revenues Down 18 Percent
Sep 1, 2023
360Dx Top 30 Ticks Down in August
Aug 31, 2023
Burning Rock Biotech Q2 Revenues up 12 Percent
Jul 5, 2023
360Dx Top 30 Rebounds in June, Rising 4 Percent
May 30, 2023
Burning Rock Biotech Q1 Revenues up 5 Percent
May 1, 2023
360Dx Top 30 Slides 2 Percent in April
Nov 16, 2022
Burning Rock Biotech Q3 Revenues Climb 22 Percent
Sep 1, 2022
360Dx Top 30 Tumbles in August
Jul 1, 2022